Huakang Tu1,2, Liping Sun1, Xiao Dong3, Yuehua Gong1, Qian Xu1, Jingjing Jing1, Roberd M Bostick4, Xifeng Wu2, Yuan Yuan1. 1. Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Affiliated Hospital of China Medical University, Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department, Shenyang, Liaoning, China. 2. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3. School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA. 4. Department of Epidemiology, Rollins School of Public Health, and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Abstract
OBJECTIVES: We aimed to assess a serological biopsy using five stomach-specific circulating biomarkers-pepsinogen I (PGI), PGII, PGI/II ratio, anti-Helicobacter pylori (H. pylori) antibody, and gastrin-17 (G-17)-for identifying high-risk individuals and predicting risk of developing gastric cancer (GC). METHODS: Among 12,112 participants with prospective follow-up from an ongoing population-based screening program using both serology and gastroscopy in China, we conducted a multi-phase study involving a cross-sectional analysis, a follow-up analysis, and an integrative risk prediction modeling analysis. RESULTS: In the cross-sectional analysis, the five biomarkers (especially PGII, the PGI/II ratio, and H. pylori sero-positivity) were associated with the presence of precancerous gastric lesions or GC at enrollment. In the follow-up analysis, low PGI levels and PGI/II ratios were associated with higher risk of developing GC, and both low (<0.5 pmol/l) and high (>4.7 pmol/l) G-17 levels were associated with higher risk of developing GC, suggesting a J-shaped association. In the risk prediction modeling analysis, the five biomarkers combined yielded a C statistic of 0.803 (95% confidence interval (CI)=0.789-0.816) and improved prediction beyond traditional risk factors (C statistic from 0.580 to 0.811, P<0.001) for identifying precancerous lesions at enrollment, and higher serological biopsy scores based on the five biomarkers at enrollment were associated with higher risk of developing GC during follow-up (P for trend <0.001). CONCLUSIONS: A serological biopsy composed of the five stomach-specific circulating biomarkers could be used to identify high-risk individuals for further diagnostic gastroscopy, and to stratify individuals' risk of developing GC and thus to guide targeted screening and precision prevention.
OBJECTIVES: We aimed to assess a serological biopsy using five stomach-specific circulating biomarkers-pepsinogen I (PGI), PGII, PGI/II ratio, anti-Helicobacter pylori (H. pylori) antibody, and gastrin-17 (G-17)-for identifying high-risk individuals and predicting risk of developing gastric cancer (GC). METHODS: Among 12,112 participants with prospective follow-up from an ongoing population-based screening program using both serology and gastroscopy in China, we conducted a multi-phase study involving a cross-sectional analysis, a follow-up analysis, and an integrative risk prediction modeling analysis. RESULTS: In the cross-sectional analysis, the five biomarkers (especially PGII, the PGI/II ratio, and H. pylori sero-positivity) were associated with the presence of precancerous gastric lesions or GC at enrollment. In the follow-up analysis, low PGI levels and PGI/II ratios were associated with higher risk of developing GC, and both low (<0.5 pmol/l) and high (>4.7 pmol/l) G-17 levels were associated with higher risk of developing GC, suggesting a J-shaped association. In the risk prediction modeling analysis, the five biomarkers combined yielded a C statistic of 0.803 (95% confidence interval (CI)=0.789-0.816) and improved prediction beyond traditional risk factors (C statistic from 0.580 to 0.811, P<0.001) for identifying precancerous lesions at enrollment, and higher serological biopsy scores based on the five biomarkers at enrollment were associated with higher risk of developing GC during follow-up (P for trend <0.001). CONCLUSIONS: A serological biopsy composed of the five stomach-specific circulating biomarkers could be used to identify high-risk individuals for further diagnostic gastroscopy, and to stratify individuals' risk of developing GC and thus to guide targeted screening and precision prevention.
Authors: Meira Epplein; Wei-Cheng You; Julia Butt; Yang Zhang; Laura H Hendrix; Christian C Abnet; Gwen Murphy; Wei Zheng; Xiao-Ou Shu; Shoichiro Tsugane; You-Lin Qiao; Philip R Taylor; Taichi Shimazu; Keun-Young Yoo; Sue K Park; Jeongseon Kim; Sun Ha Jee; Tim Waterboer; Michael Pawlita; Kai-Feng Pan Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-08-29 Impact factor: 4.254
Authors: Maomao Cao; He Li; Dianqin Sun; Lin Lei; Jiansong Ren; Jufang Shi; Ni Li; Ji Peng; Wanqing Chen Journal: Chin J Cancer Res Date: 2020-10-31 Impact factor: 5.087
Authors: Kryssia Rodriguez; Marilisa Franceschi; Antonio Ferronato; Lorenzo Brozzi; Antonio Antico; Maria Piera Panozzo; Arianna Massella; Barbara Pertoldi; Alice Morini; Alberto Barchi; Michele Russo; Pellegrino Crafa; Lorella Franzoni; Lucio Cuoco; Gianluca Baldassarre; Francesco Di Mario Journal: Acta Biomed Date: 2022-08-31
Authors: M Song; M C Camargo; S J Weinstein; G Murphy; N D Freedman; J Koshiol; R Z Stolzenberg-Solomon; C C Abnet; S Männistö; D Albanes; C S Rabkin Journal: Aliment Pharmacol Ther Date: 2017-12-15 Impact factor: 8.171